

NCT ID	NCT05019534
Title	Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2021-08-25
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Camrelizumab, Cetuximab Injection [Erbixux], Vemurafenib Oral Tablet [Zelboraf]
Tags	MSS/ MMRp
NCT ID	NCT04591431
Title	The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Phase	Phase 2
Date Added	2020-10-19
Location	Italy
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Alectinib, Atezolizumab, Brigatinib, Cobimetinib, Entrectinib, Erlotinib, everolimus, Ipatasertib, Ipilimumab, Itacitinib, Lapatinib, Nivolumab, Oncology Drugs, palbociclib, Pemigatinib, Pertuzumab, Ponatinib, Trastuzumab, Trastuzumab emtansine, Vemurafenib, Vismogedib
Tags	MSS/ MMRp
NCT ID	NCT03985891
Title	The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
Phase	Phase 1/Phase 2
Date Added	2019-06-14
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04984369
Title	The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
Phase	Phase 2
Date Added	2021-07-30
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Cetuximab Injection [Erbixux], HLX208
Tags	MSS/ MMRp
NCT ID	NCT02925234
Title	The Drug Rediscovery Protocol (DRUP Trial)
Phase	Phase 2

Date Added	2016-10-05
Location	Netherlands
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Abemaciclib, afatinib, Alectinib, Alpelisib, Atezolizumab and Bevacizumab, Axitinib, Cabozantinib, Crizotinib, Dabrafenib, Dabrafenib and trametinib, Dacomitinib, durvalumab, Entrectinib, Erdafitinib, Erlotinib, Ipilimumab and nivolumab, Lenvatinib, lorlatinib, Nilotinib, Nivolumab, Olaparib, palbociclib, panitumumab, Pembrolizumab, Regorafenib, ribociclib, Rucaparib, Sunitinib, Talazoparib, Trametinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT04535024
Title	The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer
Phase	Phase 2
Date Added	2020-09-01
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Sintilimab
Tags	MSS/ MMRp

NCT ID	NCT04948034
Title	The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)
Phase	Phase 2
Date Added	2021-07-01
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Fruquintinib, Tislelizumab
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT02298959
Title	Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
Phase	Phase 1
Date Added	2014-11-24
Location	Florida, United States Maryland, United States Massachusetts, United States Canada
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pembrolizumab, Ziv-Aflibercept, Keytruda, Zaltrap
Tags	MSS/ MMRp

NCT ID	NCT03502733
Title	Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
Phase	Phase 1

Date Added	2018-04-19
Location	Maryland, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Copanlisib, Ipilimumab, Nivolumab, Aliqopa, Opdivo
Tags	MSS/ MMRp
NCT ID	NCT05673148
Title	Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Phase	Phase 3
Date Added	2023-01-06
Location	Arizona, United States California, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Iowa, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Chemotherapy
Tags	MSS/ MMRp